Exclusive Summary

• Antibodies targeting LIV-1 are conjugated to small molecule toxins. UB656 recognizes and binds to LIV-1 on the surface of tumor cells, and the ADC-target complex enters the lysosomes of tumor cells through endocytosis, releasing small molecule toxins to kill tumor cells.